Sarepta (SRPT) Pops Higher as Glaxo's DMD Drug Drisapersen Falters
Tweet Send to a Friend
Down)
Sarepta Therapeutics (Nasdaq: SRPT) shares are active Wednesday afternoon following speculation that it might be able to pick up where GlaxoSmithKline (NYSE: GSK) is leaving off.
Biotech stock watcher Adam Feuerstein commented today that duchenne muscular dystrophy (DMD) patients trated with Glaxo's drisapersen are said to have been hospitalized due to kidney toxicity and low platelet counts.
Though the announcement was made last Sunday during a medical meeting in Rome, Feuerstein speculates that Sarepta might be meeting with FDA reps over the possibility of accelerating the approval of the company's DMD drug eteplirsen "based on a completed phase II study." Eteplirsen's record to-date has been relatively sterling.
Shares of Sarepta are up 7.5 percent on heavy volume today. The stock is a bit of a favorite with short sellers, as 3.84 million shares, or 14.5 percent of float, are currently being held short.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Biotech stock watcher Adam Feuerstein commented today that duchenne muscular dystrophy (DMD) patients trated with Glaxo's drisapersen are said to have been hospitalized due to kidney toxicity and low platelet counts.
Though the announcement was made last Sunday during a medical meeting in Rome, Feuerstein speculates that Sarepta might be meeting with FDA reps over the possibility of accelerating the approval of the company's DMD drug eteplirsen "based on a completed phase II study." Eteplirsen's record to-date has been relatively sterling.
Shares of Sarepta are up 7.5 percent on heavy volume today. The stock is a bit of a favorite with short sellers, as 3.84 million shares, or 14.5 percent of float, are currently being held short.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- Clearwire (CLWR) Active as DISH Eyes Lightsquared Spectrum
- Apple (AAPL) Continues Higher
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
